Takuya Azechi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Takuya Azechi has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Kuniyoshi Sato
Department of Pharmacy, Juntendo University Hospital, Tokyo, Japan
2 shared publicationsToshimi Kimura
Faculty of Pharmacy, Juntendo University, 6-8-1 Hinode, Urayasu, Chiba, 279-0013, Japan
2 shared publications- Akihiro Sato
Clinical Research Support Office, National Cancer Center Hospital East, Kashiwa 277-8577, Japan
1 shared publication Ayumi Nakai
Department of Pharmacy, Juntendo University Hospital, Tokyo, Japan
1 shared publication- Chika Nitani
Department of Pediatric Hematology and Oncology, Osaka City General Hospital, Osaka, Japan
1 shared publication Eiji Kose
Faculty of Pharmacy, Juntendo University, 6-8-1 Hinode, Urayasu, Chiba, 279-0013, Japan
1 shared publication
Latest Publications
- Open Access
- 28 May 2026
- Published by Springer Nature in Journal of Pharmaceutical Health Care and Sciences
- Vol. 12 (1)
A survey of community pharmacists’ perceptions, attitudes, and practices regarding support for physical activity, exercise, and frailty
Background: Community pharmacists are expected to contribute to frailty prevention through physical activity and exercise support. However, their definitive involvement and the factors influencing their engagement remain unclear. Methods: An anonymous online questionnaire-based survey targeting pharmacists working in community pharmacies or the pharmacy sections of drugstores was conducted from November 2024 to March 2025. The survey assessed their recognition, attitudes, and practices regarding frailty and support for physical activity and exercise. Frailty assessment was defined as responses of “occasionally” or more. Descriptive statistics and multivariate logistic regression were used for the analysis. Results: Among the 1,054 responses, 89.8% expressed positive attitudes toward supporting physical activity and exercise, but insufficient knowledge and lack of confidence were major barriers. Furthermore, although 88.3% of respondents considered awareness of the patient frailty status to be important and 60.1% recognized the importance of pharmacist-led frailty assessments, only 29.6% performed such assessments. The independent factors associated with frailty assessment were implementation of pharmacist-led support for physical activity and exercise (adjusted odds ratio [aOR]: 2.46; 95% confidence interval [CI]: 1.73–3.50), recognition of the importance of frailty assessment (aOR: 2.83; 95% CI: 1.97–4.07), and availability of educational opportunities related to physical activity and exercise support (aOR: 1.62; 95% CI: 1.12–2.34). Conclusion: While many pharmacists recognize the importance of frailty care, their involvement remains limited due to insufficient knowledge. Practical and educational experiences regarding physical activity and exercise support were significantly associated with frailty assessment practices, suggesting their importance in promoting future pharmacists’ engagement in frailty prevention.
- 28 May 2026
- Published by Springer Nature in Journal of Pharmaceutical Health Care and Sciences
- Vol. 12 (1)
Open AccessA survey of community pharmacists’ perceptions, attitudes, and practices regarding support for physical activity, exercise, and frailty
Background: Community pharmacists are expected to contribute to frailty prevention through physical activity and exercise support. However, their definitive involvement and the factors influencing their engagement remain unclear. Methods: An anonymous online questionnaire-based survey targeting pharmacists working in community pharmacies or the pharmacy sections of drugstores was conducted from November 2024 to March 2025. The survey assessed their recognition, attitudes, and practices regarding frailty and support for physical activity and exercise. Frailty assessment was defined as responses of “occasionally” or more. Descriptive statistics and multivariate logistic regression were used for the analysis. Results: Among the 1,054 responses, 89.8% expressed positive attitudes toward supporting physical activity and exercise, but insufficient knowledge and lack of confidence were major barriers. Furthermore, although 88.3% of respondents considered awareness of the patient frailty status to be important and 60.1% recognized the importance of pharmacist-led frailty assessments, only 29.6% performed such assessments. The independent factors associated with frailty assessment were implementation of pharmacist-led support for physical activity and exercise (adjusted odds ratio [aOR]: 2.46; 95% confidence interval [CI]: 1.73–3.50), recognition of the importance of frailty assessment (aOR: 2.83; 95% CI: 1.97–4.07), and availability of educational opportunities related to physical activity and exercise support (aOR: 1.62; 95% CI: 1.12–2.34). Conclusion: While many pharmacists recognize the importance of frailty care, their involvement remains limited due to insufficient knowledge. Practical and educational experiences regarding physical activity and exercise support were significantly associated with frailty assessment practices, suggesting their importance in promoting future pharmacists’ engagement in frailty prevention.
- Open Access
- 14 November 2024
- Published by MDPI AG in Current Oncology
- Vol. 31 (11) , 7155-7164
Population Pharmacokinetics of Tamibarotene in Pediatric and Young Adult Patients with Recurrent or Refractory Solid Tumors
Tamibarotene is a synthetic retinoid that inhibits tumor cell proliferation and promotes differentiation. We previously reported on the safety and tolerability of tamibarotene in patients with recurrent or refractory solid tumors. Therefore, in this study, we aimed to evaluate the pharmacokinetic properties of tamibarotene and construct a precise pharmacokinetic model. We also conducted a non-compartmental analysis and population pharmacokinetic (popPK) analysis based on the results of a phase I study. Targeted pediatric and young adult patients with recurrent or refractory solid tumors were administered tamibarotene at doses of 4, 6, 8, 10, and 12 g/m2/day. Serum tamibarotene concentrations were evaluated after administration, and a popPK model was constructed for tamibarotene using Phoenix NLME. During model construction, we considered the influence of various parameters (weight, height, body surface area, and age) as covariates. Notably, 22 participants were included in this study, and 109 samples were analyzed. A two-compartment model incorporating lag time was selected as the base model. In the final model, the body surface area was included as a covariate for apparent total body clearance, the central compartment volume of distribution, and the peripheral compartment volume of distribution. Visual prediction checks and bootstrap analysis confirmed the validity and predictive accuracy of the final model as satisfactory.
- 14 November 2024
- Published by MDPI AG in Current Oncology
- Vol. 31 (11) , 7155-7164
Open AccessPopulation Pharmacokinetics of Tamibarotene in Pediatric and Young Adult Patients with Recurrent or Refractory Solid Tumors
Tamibarotene is a synthetic retinoid that inhibits tumor cell proliferation and promotes differentiation. We previously reported on the safety and tolerability of tamibarotene in patients with recurrent or refractory solid tumors. Therefore, in this study, we aimed to evaluate the pharmacokinetic properties of tamibarotene and construct a precise pharmacokinetic model. We also conducted a non-compartmental analysis and population pharmacokinetic (popPK) analysis based on the results of a phase I study. Targeted pediatric and young adult patients with recurrent or refractory solid tumors were administered tamibarotene at doses of 4, 6, 8, 10, and 12 g/m2/day. Serum tamibarotene concentrations were evaluated after administration, and a popPK model was constructed for tamibarotene using Phoenix NLME. During model construction, we considered the influence of various parameters (weight, height, body surface area, and age) as covariates. Notably, 22 participants were included in this study, and 109 samples were analyzed. A two-compartment model incorporating lag time was selected as the base model. In the final model, the body surface area was included as a covariate for apparent total body clearance, the central compartment volume of distribution, and the peripheral compartment volume of distribution. Visual prediction checks and bootstrap analysis confirmed the validity and predictive accuracy of the final model as satisfactory.
- Open Access
- 4 March 2024
- Published by Springer Nature in Journal of Pharmaceutical Health Care and Sciences
- Vol. 10 (1) , 1-8
Vaccination status, incidence of adverse events, and awareness of COVID-19 vaccine among outpatients undergoing chemotherapy
Background: Cancer has been identified as a risk factor for severe illness and mortality in coronavirus disease (COVID-19), underscoring the importance of recommending COVID-19 vaccinations to patients with cancer. However, few reports have focused on the vaccination status and the incidence of adverse events among patients with cancer. In this study, we aimed to evaluate the vaccination status, incidence of adverse events, concerns, and anxiety related to COVID-19 vaccination among patients with cancer. In addition, we explored the utilization of information sources by these patients and the ease of use. Methods: A survey was conducted among outpatients undergoing chemotherapy who received medication counseling from a pharmacist at Juntendo University Hospital. Responses were gathered from 60 out of the 143 participants. Of the respondents, 96.7% had received two doses of the COVID-19 vaccine. Results: Common adverse events included pain at the injection site, fever, and fatigue, which were experienced by nearly half of the respondents. Approximately 80% expressed some concern regarding vaccination, with predominant concerns about timing in the context of ongoing cancer treatment and surgery. Among the respondents, 41.7% consulted primary care physicians regarding the vaccine, with only one mentioning consultation with hospital pharmacists. Notably, primary care physicians were considered the most approachable and useful healthcare professionals. Conclusions: These results suggest that patients with cancer can safely receive the vaccine, comparable to patients without cancer. However, they still harbor concerns, even when seeking advice from primary care physicians. Few patients consulted pharmacists about vaccination, highlighting an opportunity for pharmacist intervention. Pharmacists fostering trust with patients with cancer is imperative to explore pharmacist intervention methods to promote the continued administration of COVID-19 vaccines and enhance the quality of life for them.
- 4 March 2024
- Published by Springer Nature in Journal of Pharmaceutical Health Care and Sciences
- Vol. 10 (1) , 1-8
Open AccessVaccination status, incidence of adverse events, and awareness of COVID-19 vaccine among outpatients undergoing chemotherapy
Background: Cancer has been identified as a risk factor for severe illness and mortality in coronavirus disease (COVID-19), underscoring the importance of recommending COVID-19 vaccinations to patients with cancer. However, few reports have focused on the vaccination status and the incidence of adverse events among patients with cancer. In this study, we aimed to evaluate the vaccination status, incidence of adverse events, concerns, and anxiety related to COVID-19 vaccination among patients with cancer. In addition, we explored the utilization of information sources by these patients and the ease of use. Methods: A survey was conducted among outpatients undergoing chemotherapy who received medication counseling from a pharmacist at Juntendo University Hospital. Responses were gathered from 60 out of the 143 participants. Of the respondents, 96.7% had received two doses of the COVID-19 vaccine. Results: Common adverse events included pain at the injection site, fever, and fatigue, which were experienced by nearly half of the respondents. Approximately 80% expressed some concern regarding vaccination, with predominant concerns about timing in the context of ongoing cancer treatment and surgery. Among the respondents, 41.7% consulted primary care physicians regarding the vaccine, with only one mentioning consultation with hospital pharmacists. Notably, primary care physicians were considered the most approachable and useful healthcare professionals. Conclusions: These results suggest that patients with cancer can safely receive the vaccine, comparable to patients without cancer. However, they still harbor concerns, even when seeking advice from primary care physicians. Few patients consulted pharmacists about vaccination, highlighting an opportunity for pharmacist intervention. Pharmacists fostering trust with patients with cancer is imperative to explore pharmacist intervention methods to promote the continued administration of COVID-19 vaccines and enhance the quality of life for them.
- Open Access
- 15 December 2022
- Published by American Society for Microbiology in Journal of Microbiology & Biology Education
- Vol. 23 (3)
Evaluation of Knowledge Regarding the Use of Antibiotics among Pharmacy Undergraduates in Japan
Antimicrobial resistance (AMR) is a global threat to human health. Education on antibiotics is essential for AMR prevention, and training should be provided for undergraduate pharmacy students.
- 15 December 2022
- Published by American Society for Microbiology in Journal of Microbiology & Biology Education
- Vol. 23 (3)
Open AccessEvaluation of Knowledge Regarding the Use of Antibiotics among Pharmacy Undergraduates in Japan
Antimicrobial resistance (AMR) is a global threat to human health. Education on antibiotics is essential for AMR prevention, and training should be provided for undergraduate pharmacy students.